ArticleTherapeutic delivery2025
Development of high-solubility amorphous sulfasalazine: effect of hydrogen bonding.
Article in Therapeutic delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSulphasalazine (Sulf) is a class IV compound with low aqueous solubility and low permeability which limit its therapeutic activity. This work aims to apply choline chloride (CC) and choline hydroxide (CH) as a hydrogen bond acceptor with Sulf for the production of Sulf salt. MATERIALS AND
methodNew compounds were prepared and characterized by XRD, DSC, and FT-IR. Drug solubility was evaluated in different media including pure water, and buffer pH 1.2, 4.5, and 6.8 were evaluated.
resultsThe diffractogram pattern of the Sulf-CH shows a smooth and low-intensity diffraction which may indicate amorphization of the drug molecule. The FT-IR spectra confirm participation of the carboxyl group of Sulf in the formation of hydrogen bonding between Sulf and CH through salt formation which helps to enhance drug solubility. Solubility of Sulf-CH significantly increased up to 10,000-folds in pure water. Sulf-CC caused up to 2-folds enhancement in drug solubility.
conclusionThe difference in the solubility of Sulf-CC and Sulf-CH may suggest that each of these compounds involve different intermolecular interactions which were also confirmed by FT-IR, XRD, and DSC results. This effect can influence drug bioavailability and enhance its therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.